SEC Tracker
Get the app

Zymeworks ZYME

Zymeworks reports $81.13M net loss for 2025.

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Net loss of $81.13 million for the year ended Dec 31, 2025.
  2. Annual meeting of stockholders scheduled for Dec 15, 2026.
  3. KPMG LLP to be auditors for the year ending Dec 31, 2026.

Written from the DEF 14A on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Zymeworks files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Anaptysbio ANAB public float $633M, Dec 31, 2025
  2. Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
  3. ImmunityBio IBRX public float $690M, Jun 30, 2025
  4. Evoke Pharma EVOK
  5. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.